Artesunate for pulmonary arterial hypertension safety study
Treatments studied
Part of Lungs & breathing clinical trials.
This trial tests if artesunate, a malaria drug, is safe and tolerable for people with pulmonary arterial hypertension (PAH). It may offer a new treatment option for PAH patients whose symptoms persist despite using two or more standard therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have pulmonary arterial hypertension (PAH) and are in World Health Organization (WHO) functional class I, II, or III.
- You are currently taking at least two PAH medications (like sildenafil, riociguat, bosentan, ambrisentan, or prostacyclin drugs) at the highest doses you can tolerate.
- You do not have any other serious medical condition that the study doctor thinks might interfere.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medicine called ambrisentan for people with early, low-risk pulmonary arterial hypertension. The goal is to see if starting treatment early can help manage the condition before it gets worse.
This trial tests a new combination of three medicines (including an experimental drug called sotatercept) for people recently diagnosed with PAH. The goal is to see if this early, powerful treatment works better than standard care in improving heart and lung function.
This study tests a drug called treprostinil to see if it is safe and effective for people with intermediate-risk pulmonary arterial hypertension (PAH), a condition of high blood pressure in the lungs. If you join, you may receive the study drug along with your usual PAH medications, which could help improve your symptoms and slow the disease.
This trial tests a new medication called REGN13335 for people with pulmonary arterial hypertension (PAH). It aims to see if the drug can improve symptoms and function compared to standard care alone.
This trial tests whether adding the study drug sotatercept to your current PAH therapy along with a home exercise program can help you feel better and be more active. It's for people with certain types of PAH who are stable on their current treatment.
This study looks at the long-term effects of a medicine called selexipag on people with pulmonary hypertension caused by schistosomiasis, a parasitic infection. It aims to see if selexipag improves outcomes compared to standard care.
Hear when a new Pulmonary Arterial Hypertension (PAH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.